Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | London | Healthcare | Pharmaceuticals | £233.38B | 72.6x | -6.6 | GBX 14,823.60 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £215.43B | 18.5x | 0.86 | GBX 4,409.42 | -7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £198.53B | 25.9x | -0.84 | GBX 23,682.69 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £198.53B | 25.9x | -0.84 | GBX 24,959.33 | -11.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbott Laboratories L | London | Healthcare | Healthcare Equipment & Supplies | £173.18B | 17.2x | 0.12 | GBX 9,896.26 | 17.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £158.64B | 18.6x | -0.95 | GBX 8,309.29 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £157.92B | 29.7x | 1.59 | GBX 10,124 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £149B | 11.6x | 0 | GBX 5,928.53 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £98.17B | 273.5x | -2.87 | GBX 7,892.36 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essilor International | London | Healthcare | Healthcare Equipment & Supplies | £97.28B | 47.7x | 47.53 | GBX 21,321.28 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £95.12B | 20.6x | 6.78 | GBX 7,771.55 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £54.20B | 21.2x | -0.42 | GBX 1,336.50 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.9% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £43.54B | 18.2x | -11.37 | GBX 10,009.79 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Siemens Healthineers | London | Healthcare | Healthcare Equipment & Supplies | £42.96B | 26.4x | 0.8 | GBX 3,837.23 | -22.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £35.12B | 58x | GBX 49,881.66 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
HALEON | London | Healthcare | Pharmaceuticals | £34.56B | 25x | 0.6 | GBX 380.50 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £27.47B | 42.8x | 0.12 | GBX 44,700.36 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IDEXX Laboratories | London | Healthcare | Healthcare Equipment & Supplies | £25.10B | 38x | 5.79 | GBX 30,808.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Humana | London | Healthcare | Healthcare Providers & Services | £24.25B | 26.6x | -0.58 | GBX 19,785.71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
UCB L | London | Healthcare | Pharmaceuticals | £22.33B | 24.4x | 0.11 | GBX 11,736.80 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius SE Co KGaA | London | Healthcare | Healthcare Providers & Services | £18.86B | 21.1x | 0.11 | GBX 3,344.04 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coloplast AS | London | Healthcare | Healthcare Equipment & Supplies | £18.22B | 32.3x | -12.34 | GBX 8,069.83 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £17.74B | -8.1x | -0.6 | GBX 1,804.34 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Koninklijke Philips | London | Healthcare | Healthcare Equipment & Supplies | £16.68B | -23.4x | 0.42 | GBX 1,798.32 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £13.17B | GBX 2,997.34 | 13.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Sonova Holding | London | Healthcare | Healthcare Equipment & Supplies | £13.05B | 24.9x | -4.16 | GBX 21,772.34 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £13.02B | 10.5x | 0.26 | GBX 8,856.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Fresenius Medical Care | London | Healthcare | Healthcare Providers & Services | £10.49B | 22.8x | 2.98 | GBX 3,572.59 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Align Tech | London | Healthcare | Healthcare Equipment & Supplies | £9.41B | 30.1x | -8.77 | GBX 12,787.93 | -33% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £9.39B | 10.5x | 0.12 | GBX 14,866.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Smith & Nephew | London | Healthcare | Healthcare Equipment & Supplies | £8.59B | 27.7x | 0.48 | GBX 983.60 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
Recordati Industria | London | Healthcare | Pharmaceuticals | £8.55B | 23.9x | 3.28 | GBX 4,124.90 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE FRA | London | Healthcare | Biotechnology & Medical Research | £8.21B | 33.3x | 0.62 | GBX 4,261.68 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £6.96B | 23x | 0.44 | GBX 2,044.59 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £6.67B | 104.8x | -1.43 | GBX 3,091.43 | -17.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £6.41B | 21.1x | -0.47 | GBX 7,793.03 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £5.95B | 21x | 0.39 | GBX 4,218.72 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
William Demant | London | Healthcare | Healthcare Equipment & Supplies | £5.49B | 16.8x | 0.43 | GBX 2,555.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ConvaTec Group | London | Healthcare | Healthcare Equipment & Supplies | £5.20B | 37.5x | 0.73 | GBX 253.40 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16% Upside | Upgrade to Pro+ | |
Grifols Pref | London | Healthcare | Pharmaceuticals | £4.72B | 35.1x | 0.11 | GBX 525.84 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £4.72B | 35.1x | 0.11 | GBX 689.09 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DiaSorin | London | Healthcare | Healthcare Equipment & Supplies | £4.54B | 29x | 1.55 | GBX 8,439.15 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Carl Zeiss Meditec | London | Healthcare | Healthcare Equipment & Supplies | £4.25B | 31.7x | -0.71 | GBX 4,824.46 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.16B | 15.4x | 0.16 | GBX 1,885 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.6% Upside | Upgrade to Pro+ | |
Getinge AB | London | Healthcare | Healthcare Equipment & Supplies | £4.11B | 32.5x | -0.99 | GBX 1,506.58 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sectra AB | London | Healthcare | Healthcare Equipment & Supplies | £4.06B | 88.7x | 2.11 | GBX 2,105.58 | 40.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £3.97B | 7.9x | 0.07 | GBX 1,067.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £3.79B | 39.9x | 0.6 | GBX 1,721.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ambu | London | Healthcare | Healthcare Equipment & Supplies | £3.49B | 93x | 2.68 | GBX 1,313.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £3.46B | -44x | 0.92 | GBX 4,829.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |